Alendronate plus cholecalciferol for the treatment of osteoporosis

By Heaney Robert P  

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 23-27

Future Medicine

Access to resources Recommend Favorite

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

By Chapple C   DuBeau C   Ebinger U   Rekeda L   Viegas A  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2347-2358

Informa Healthcare

Access to resources Recommend Favorite

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

By Villiers T.   Chines A.   Palacios S.   Lips P.   Sawicki A.   Levine A.   Codreanu C.   Kelepouris N.   Brown J.  

Osteoporosis International, Vol. 22, Iss. 2, 2011-02 ,pp. : 567-576

Springer Publishing Company

Access to resources Recommend Favorite

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

By Emkey Ronald   Koltun William   Beusterien Kathleen   Seidman Larry   Kivitz Alan   Devas Vipul   Masanauskaite Daiva  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1895-1903

Informa Healthcare

Access to resources Recommend Favorite

Influence of Cholecalciferol Supplementation in Hemodialysis Patients on Monocyte Subsets: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

By  

Nephron Clin Pract, Vol. 123, Iss. 3-4, 2013-08 ,pp. : 209-219

Karger

Access to resources Recommend Favorite